Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...